Adlai Nortye (ANL) Return on Assets (2024 - 2025)
Adlai Nortye's (ANL) quarterly Return on Assets came in at 0.0% in Q4 2025, little changed year-on-year from 0.0% in Q4 2024, and down 34.6% on a QoQ basis from 0.0% in Q2 2025.
Adlai Nortye (ANL) Return on Assets (2024 - 2025) Analysis & Trends
Adlai Nortye (ANL) has 2 years of Return on Assets data on file, last reported at 0.0% in Q4 2025.
- On a quarterly basis, Return on Assets changed 0.0% year-over-year to 0.0% in Q4 2025; TTM through Dec 2025 was 0.0%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 0.01%, changed 0.0% from the prior year.
- Return on Assets for Q4 2025 stood at 0.0%, down from 0.0% in the prior quarter.
- Over the last five years, Return on Assets for ANL reached as high as 0.0% in Q4 2024 and fell as low as 0.0% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | -0.69% |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -0.01% |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | -0.80% |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | 0.00% |
| 10 | Adlai Nortye | 1.15 Bn | 1.14 Bn | - | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.00% |
| Jun 30, 2025 | 0.00% |
| Dec 31, 2024 | 0.00% |